FDA Cuts Monitoring After Imdelltra's First Two Doses to Six to Eight Hours for Small Cell Lung Cancer

FDA Approves Shorter Monitoring for First Two Tarlatamab Doses in ES-SCLC

The FDA reduced the recommended monitoring time for the first 2 doses of tarlatamab to 6 to 8 hours in extensive-stage small cell lung cancer.

FDA Cuts Monitoring After Imdelltra's First Two Doses to Six to Eight Hours for Small Cell Lung Cancer

FDA cut monitoring after Imdelltra's first two doses from 22 to 24 hours to 6 to 8 hours, which may bring treatment closer to home for some patients.

FDA reduces monitoring time for Amgen’s Imdelltra infusions

The FDA has approved an update to the prescribing information for Amgen’s Imdelltra, cutting the recommended monitoring time for ES-SCLC patients after their first two infusions.

FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®